Correlation between tumor histology, steroid receptor status, and adenosine deaminase complexing protein immunoreactivity in ovarian cancer.

Rao BR, Slotman BJ, Geldof AA, Dinjens WN
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 1990 · doi:10.1097/00004347-199001000-00004 · PMID:2152891
OA: closed
Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-30 ⓘ

This study investigated adenosine deaminase complexing protein immunoreactivity in ovarian tumors, finding associations with specific histologic subtypes and steroid receptor status but concluding its clinical value is limited.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-30 · read from full text ⓘ

This study evaluated adenosine deaminase complexing protein (ADCP) immunoreactivity in 40 ovarian tumors to determine its correlation with histology and steroid receptor status. The researchers found that ADCP reactivity was significantly more frequent in mucinous, well-differentiated, and Stage I carcinomas, as well as in tumors exhibiting high androgen receptor levels but lacking estrogen receptors. However, the analysis revealed no correlation between ADCP reactivity and receptor status once the data was stratified by histologic grade. Consequently, the authors concluded that determining ADCP reactivity has limited clinical value for characterizing ovarian cancer. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Adenosine deaminase complexing protein (ADCP) immunoreactivity was investigated in 40 ovarian tumors and correlated with clinicopathologic parameters, including tumor steroid receptor content. Ten (29%) of 34 common epithelial ovarian carcinomas showed ADCP reactivity. Reactivity for ADCP was seen more frequently in mucinous (100%; p less than 0.001), well-differentiated (73%; p less than 0.001) and Stage I (56%; p less than 0.05) ovarian carcinomas. Furthermore, tumors that contained high levels of androgen receptors and tumors that did not contain estrogen receptors were more frequently ADCP positive (p less than 0.05). However, after stratifying for histologic grade, no correlation between ADCP reactivity and receptor status was found. Determination of ADCP reactivity appears to be of limited value in ovarian cancer.
Full text 1,001 characters · extracted from oa-doi-fallback · click to expand
Correlation Between Tumor Histology, Steroid Receptor Status, and Adenosine Deaminase Complexing Protein Immunoreactivity in Ovarian Cancer - B R Rao - B J Slotman - A A Geldof - W N M Dinjens Summary: Adenosine deaminase complexing protein (ADCP) immunoreactivity was investigated in 40 ovarian tumors and correlated with clinicopathologic parameters, including tumor steroid receptor content. Ten (29%) of 34 common epithelial ovarian carcinomas showed ADCP reactivity. Reactivity for ADCP was seen more frequently in mucinous (100%; p < 0.001), well-differentiated (73%; p < 0.001) and Stage I (56%; p < 0.05) ovarian carcinomas. Furthermore, tumors that contained high levels of androgen receptors and tumors that did not contain estrogen receptors were more frequently ADCP positive (p < 0.05). However, after stratifying for histologic grade, no correlation between ADCP reactivity and receptor status was found. Determination of ADCP reactivity appears to be of limited value in ovarian cancer.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-04T09:26:46.659050+00:00
unpaywall
last seen: 2026-10-08T06:33:43.470499+00:00